Premium
The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors
Author(s) -
Herold Christopher L,
Behm David J,
Buckley Peter T,
Foley James J,
Wixted William E,
Sarau Henry M,
Douglas Stephen A
Publication year - 2003
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705251
Subject(s) - urotensin ii , antagonist , receptor , receptor antagonist , endocrinology , competitive antagonist , medicine , pharmacology , biology , chemistry
The functional activity of the peptidic neuromedin B receptor antagonist BIM‐23127 was investigated at recombinant and native urotensin‐II receptors (UT receptors). Human urotensin‐II (hU‐II) promoted intracellular calcium mobilization in HEK293 cells expressing the human UT (hUT) or rat UT (rUT) receptors with pEC 50 values of 9.80±0.34 ( n =6) and 9.06±0.32 ( n =4), respectively. While BIM‐23127 alone had no effect on calcium responses in either cell line, it was a potent and competitive antagonist at both hUT (p A 2 =7.54±0.14; n =3) and rUT (p A 2 =7.70±0.05; n =3) receptors. Furthermore, BIM‐23127 reversed hU‐II‐induced contractile tone in the rat‐isolated aorta with a pIC 50 of 6.66±0.04 ( n =4). In conclusion, BIM‐ 23127 is the first hUT receptor antagonist identified to date and should not be considered as a selective neuromedin B receptor antagonist. British Journal of Pharmacology (2003) 139 , 203–207. doi: 10.1038/sj.bjp.0705251